chronic
obstruct
pulmonari
diseas
copd
debilit
respiratori
diseas
one
lead
caus
morbid
mortal
worldwid
character
persist
respiratori
symptom
airflow
limit
due
abnorm
lower
airway
follow
consist
exposur
noxiou
particl
gase
acut
exacerb
copd
aecopd
character
increas
cough
purul
sputum
product
dyspnea
aecopd
mostli
associ
infect
caus
common
cold
virus
bacteria
coinfect
chronic
persist
infect
nontyp
haemophilu
influenza
nthi
gramneg
coccobacillu
contribut
almost
half
infect
exacerb
caus
bacteria
support
report
nthi
commonli
isol
sputum
copd
patient
exacerb
persist
colon
nthi
lower
airway
requir
plethora
phenotyp
adapt
virul
mechan
develop
time
cope
chang
environment
pressur
airway
host
immunoinflammatori
respons
chronic
inhal
noxiou
irrit
copd
caus
chang
balanc
lung
microbiom
abnorm
inflammatori
respons
impair
airway
immun
system
condit
significantli
provid
opportunist
platform
nthi
colon
infect
result
viciou
circl
episod
larg
inflamm
consequ
multipl
interact
airway
immun
cell
nthi
accumul
contribut
copd
exacerb
may
result
worsen
clinic
statu
review
discuss
detail
interplay
crosstalk
airway
immun
resid
nthi
effect
aecopd
better
understand
nthi
pathogenesi
copd
patient
lung
vital
organ
involv
ga
exchang
vascular
system
extern
environ
thu
greatli
expos
environmentderiv
microorgan
includ
fungi
virus
bacteria
bronchial
tree
parenchym
tissu
lung
recent
consid
steril
colon
phylogeneticallydivers
microb
genera
firmicut
bacteroidet
proteobacteria
common
phyla
identifi
repres
total
bacteri
microbiom
healthi
airway
major
lung
microbiota
belong
normal
flora
play
import
role
pulmonari
epitheli
integr
colon
resist
homeostasi
immun
system
respiratori
tract
small
fraction
howev
potenti
pathogen
microorgan
involv
varieti
lung
diseas
exemplifi
genu
haemophilu
nontyp
haemophilu
influenza
nthi
gramneg
coccobacillu
commonli
resid
human
airway
uniqu
yet
unexplain
nthi
commens
colon
nasopharynx
throat
pathogen
lower
airway
trigger
robust
inflammatori
respons
review
see
nthi
consid
potenti
opportunist
pathogen
frequent
infect
lower
respiratori
tract
lung
structur
damag
consequ
noninfecti
lung
diseas
mechan
injuri
moreov
nthi
occasion
caus
bronchiti
pneumonia
addit
lower
airway
colon
nthi
associ
diseas
progress
sever
less
noninfecti
lung
diseas
bronchiectasi
cystic
fibrosi
interstiti
lung
diseas
mostli
chronic
obstruct
pulmonari
diseas
copd
copd
sever
inflammatori
lung
diseas
character
airflow
limit
rang
patholog
chang
genet
environment
factor
trigger
onset
copd
howev
microb
includ
nthi
play
import
role
acut
exacerb
review
describ
diseas
progress
copd
context
host
immuneinteract
link
nthi
overal
impact
diseas
exacerb
copd
third
lead
caus
morbid
mortal
worldwid
expect
affect
million
peopl
accord
global
initi
chronic
obstruct
lung
diseas
gold
copd
pulmonari
diseas
manag
signific
exacerb
comorbid
may
howev
contribut
overal
sever
individu
patient
copd
character
chronic
airflow
limit
peripher
airway
rang
patholog
chang
lung
fulli
revers
usual
becom
progress
wors
time
progress
copd
associ
abnorm
inflammatori
respons
lung
noxiou
particl
gase
patholog
point
view
copd
compris
group
pulmonari
abnorm
relat
inflammatori
reaction
airway
alveoli
pulmonari
vessel
includ
pulmonari
emphysema
ii
chronic
bronchiti
iii
diseas
small
airway
pulmonari
abnorm
progress
affect
part
lung
result
increas
resist
conduct
airway
thu
chronic
airflow
obstruct
eventu
lead
declin
lung
function
emphysema
perman
loss
elast
lung
recoil
caus
elastolyt
destruct
enlarg
alveolar
wall
distal
termin
bronchiol
consequ
result
loss
alveolar
attach
small
airway
thu
limit
airflow
gaseou
exchang
chronic
bronchiti
character
consecut
chronic
cough
expector
last
month
within
year
associ
inflamm
bronchial
wall
increas
inflammatori
infiltr
hyperplasia
goblet
cell
hypertrophi
tracheobronchi
submucosa
increas
mucou
secret
final
dilat
airway
duct
airway
mm
intern
diamet
major
ciliat
epithelium
line
airway
also
either
compromis
dysfunctionn
may
replac
noncili
squamou
epitheli
cell
small
airway
diseas
hand
involv
hyperplasia
metaplasia
mucos
gland
goblet
cell
hypersecret
intralumin
mucu
macrophag
bronchiol
accumul
lymphocyt
small
bronchiol
airway
mm
less
diamet
termin
bronchiol
addit
distort
fibrosi
stenosi
tortuos
hyperplasia
hypertrophia
small
airway
smooth
muscl
also
contribut
loss
elast
lung
parenchyma
although
copd
mainli
affect
lung
also
produc
signific
extrapulmonari
consequ
result
escal
inflammatori
respons
orchestr
airway
cell
immun
mediat
comorbid
commonli
seen
copd
patient
despit
actual
mechan
respons
system
inflamm
remain
elucid
develop
copd
multifactori
cigarett
tobacco
smoke
primari
caus
copd
risk
factor
may
promot
onset
progress
copd
includ
prolong
occup
exposur
particlesgas
mine
textil
industri
air
pollut
result
biomass
combust
bronchial
hyperrespons
variabl
copd
incid
among
smoker
also
explain
genet
predisposit
defici
cuti
laxa
mutat
elastin
gene
eln
defici
caus
deleteri
homozyg
mutat
contribut
copd
case
defici
result
increas
neutrophil
elastas
activ
ultim
lead
degrad
collaps
alveoli
importantli
metaanalys
genomewid
associ
studi
gwa
genotyp
studi
reveal
multipl
singl
nucleotid
polymorph
snp
least
gene
differ
pulmonari
genom
loci
associ
copd
suscept
airway
epithelium
expos
cigarett
tobacco
smoke
compromis
tight
junction
delay
epitheli
wound
repair
moreov
cigarett
smoke
alter
basal
cell
differenti
subepitheli
extracellular
matrix
ecm
composit
thu
caus
airway
remodel
ie
goblet
cell
hyperplasia
small
airway
squamou
metaplasia
result
mucu
hypersecret
impair
mucocilliari
clearanc
airway
obstruct
tobacco
cigarett
smoke
also
enhanc
prolifer
ecm
deposit
activ
extracellular
signal
relat
kinas
erk
signal
pathway
alter
major
ecm
compon
widespread
lung
compart
copd
patient
total
increas
type
iii
collagen
fibronectin
laminin
parallel
reduc
concentr
proteoglycan
perlecan
decorin
versican
biglycan
tenascin
elastin
cigarett
inducedoverexpress
matrix
metalloproteas
mmp
elastas
also
report
may
contribut
airway
tissu
destruct
fibrosi
addit
harm
volatil
chemic
deriv
cigarett
smoke
ie
acetaldehyd
acrolein
crotonaldehyd
prone
form
carcinogen
adduct
dna
variou
protein
ie
apoliprotein
e
surfact
protein
also
dysregul
airway
epitheli
ion
transport
disrupt
phagocyt
activ
airway
phagocyt
diminish
airway
surfac
liquid
volum
numer
proteom
transcriptom
analys
unveil
crucial
impact
cigarett
tobacco
smoke
copd
diseas
progress
airway
gene
express
differenti
gene
express
studi
done
use
copd
experiment
model
clinic
sampl
ie
bronchial
epitheli
cell
sputum
plasma
blood
bronchoalveolar
lavag
bal
fluid
collect
alter
gene
involv
oxid
stress
xenobiot
metabol
antioxid
respons
dna
repair
ecm
remodel
inflammatori
respons
immun
defens
latter
two
major
interest
discuss
review
omic
data
aid
increas
knowledg
molecular
mechan
copd
may
reflect
dynam
respons
attempt
airway
epitheli
cell
repair
cytotox
injuri
primarili
trigger
inhal
irrit
deleteri
irrevers
alter
occur
interf
airway
epitheli
homeostasi
immun
defens
may
promot
copd
develop
progress
notabl
gene
alter
phagosomaland
leukocyt
transendotheli
migrat
pathway
ltm
significantli
correl
level
cell
airway
obstruct
smoker
ltm
howev
found
dysregul
copd
patient
henc
addit
clinicalphysiolog
variabl
number
gene
product
signific
differenti
gene
express
may
target
specif
proteom
signatur
biomark
earli
copd
detect
patient
monitor
diseas
subgroup
final
treatment
select
tobacco
cigarett
smoke
regul
airway
gene
express
via
two
main
mechan
alter
statu
chromatin
remodel
ii
dna
methyl
target
gene
figur
chromatin
remodel
result
disrupt
balanc
histon
acetylationdeacetyl
excess
activ
transcript
factor
includ
lipoprotein
peroxid
product
peroxinitrit
acrolein
tobacco
smoke
contribut
anomali
key
inflammatori
redoxsensit
transcript
factor
play
direct
role
cigarett
smokeinduc
airway
inflamm
describ
smokesensor
due
sensit
activ
tobacco
residu
stimul
multipl
signal
cascad
mitogenactiv
protein
mapk
kinas
mitogen
stressactiv
kinas
protein
kinas
c
zeta
kinas
ikk
complex
nemo
tobacco
residu
promot
activ
nuclear
transloc
transcript
factor
follow
complex
format
coactiv
crebbind
protein
cbp
target
dna
sequenc
note
also
intrins
histon
acetyltransferas
hat
activ
subsequ
acetyl
phosphoryl
subunit
complex
activ
pathway
differ
kinas
respect
requir
full
activ
enhanc
dna
bind
affin
complex
histon
chromatin
complex
target
sequenc
acetyl
histon
phosphoryl
histon
subunit
cbp
complex
activ
respect
hyperacetyl
core
histon
howev
fail
neutral
deacetyl
dysfunct
histon
deacetylas
peroxinitrit
nitrat
tyrosin
residu
caus
inhibit
activ
reduc
express
protein
note
peroxinitrit
byproduct
gener
immun
cellderiv
nitrit
oxid
reactiv
oxygen
speci
ro
cigarett
smoke
cigarett
tobacco
smoke
disturb
dna
methyl
statu
target
gene
sever
mechan
firstli
dna
damag
caus
cigarett
smoke
stimul
dna
methyltransferas
dnmt
activ
induc
cpg
methyl
damag
site
hypermethyl
prone
introduc
error
methyl
target
gene
result
reduc
gene
express
secondli
activ
nicotin
signal
pathway
tobacco
smoke
caus
camkiiiv
erkmapk
pathway
activ
subsequ
induc
activ
cbp
suppress
express
may
result
reduc
dna
methyl
thu
alter
level
gene
repress
dnmt
final
enhanc
activ
transcript
factor
hypoxia
induc
factor
due
high
level
carbon
monoxid
hypoxia
also
report
influenc
airway
gene
express
consequ
combinatori
effect
aberr
acetyl
histon
dna
methyl
promot
transform
chromatin
condens
structur
activ
open
conform
facilit
irregular
access
dna
transcript
machineri
henc
figur
cigarett
tobacco
smoke
sever
effect
gene
regul
nicotin
compound
smoke
alter
gene
express
two
pathway
firstli
chromatin
remodel
left
secondli
dna
methyl
right
chromatin
remodel
involv
activ
kinas
signal
pathway
activ
nuclear
transloc
transcript
factor
complex
format
specif
dna
site
intrins
histon
acetyltransferas
hat
subunit
phosphoryl
respect
wherea
cbp
acetyl
phosphoryl
acetyl
enhanc
interact
within
complex
stabil
dna
bind
complex
modifi
histon
cbpmediat
acetyl
histon
ly
phosphoryl
result
structur
chang
chromatin
condens
structur
repress
activ
open
conform
transcript
target
gene
therefor
increas
second
mechan
sever
side
effect
result
cigarett
smoke
dna
damag
nicotin
signal
could
trigger
hypermethyl
decreas
methyl
target
dna
may
lead
dna
methyl
anomali
thu
alter
dna
express
result
hypoxia
due
high
concentr
carbon
monoxid
also
contribut
alter
gene
express
aberr
gene
express
cigarett
smoke
mostli
occur
proinflammatori
gene
result
increas
product
inflammatori
mediat
amplifi
inflamm
copd
lung
upon
exposur
irregular
gene
express
variou
cell
type
airway
mechan
report
respons
increas
express
proinflammatori
gene
product
ie
cyclooxygenas
cox
pulmonari
structur
cell
bronchial
small
airway
alveolar
epitheli
cell
immun
cell
alveolar
macrophag
increas
vegf
ino
nasal
fibroblast
lymphocyt
jurkat
cell
respect
decreas
activ
antioxid
transcript
factor
bronchial
epitheli
cell
may
contribut
anatom
anomali
airway
excess
inflammatori
respons
among
smoker
cours
copd
copd
associ
chronic
inflamm
peripher
airway
orchestr
innat
adapt
immun
respons
interconnect
via
dendrit
cell
increas
number
inflammatori
cell
neutrophil
macrophag
b
lymphocyt
mast
cell
eosinophil
dendrit
cell
inflammatori
mediat
accumul
airway
lumenwal
lung
parenchyma
immun
cell
inflammatori
mediat
henc
detect
sputum
bal
fluid
copd
patient
level
accumul
posit
correl
diseas
sever
increas
number
studi
use
anim
model
clinic
tissu
report
natur
excess
airway
inflammatori
respons
copd
despit
heterogen
symptom
progress
among
copd
patient
remain
unexplain
overal
mechan
copd
inflammatori
immun
respons
depict
figur
first
line
defens
lungth
innat
immun
inflammasom
lung
structur
cell
epitheli
endotheli
cell
fibroblast
airway
smooth
muscl
cell
activ
inhal
irrit
stimul
sever
pattern
recognit
receptor
prr
tolllik
receptor
tlr
report
key
player
inflammatori
respons
caus
increas
express
releas
array
proinflammatori
mediat
chemokin
oxid
pathway
activ
bronchial
epitheli
cell
immun
cell
alveolar
macrophag
inflammatori
mediat
interleukin
il
cxc
motif
chemokin
ligand
cxcl
granulocytemacrophag
colonystimul
factor
gmcsf
granulocytecoloni
stimul
factor
gcsf
tumor
necrosi
factor
tnf
fibroblast
growth
factor
transform
growth
factor
tgf
cc
motif
chemokin
ligand
ccl
thymic
stromal
lymphopoietin
tslp
act
recruit
immun
cell
resid
cell
initi
seri
innat
immun
respons
meanwhil
activ
alveolar
macrophag
usual
patrol
lung
parenchyma
releas
proinflammatori
mediat
chemokin
leukotrien
ltb
ro
elastolyt
enzym
matrix
metalloproteas
protein
mmp
cathepsink
l
gmcsf
gcsf
enhanc
level
result
recruit
blood
monocyt
express
receptor
respect
lung
differenti
local
macrophag
interestingli
higher
express
level
found
blood
monocyt
copd
subject
may
explain
rapid
recruit
excess
accumul
monocytederiv
interstiti
macrophag
lung
tissu
copd
patient
upregul
neutrophil
chemoattractor
ltb
induc
massiv
migrat
circul
neutrophil
lung
parenchyma
transmigr
blood
neutrophil
occur
adher
granulocyt
eselectin
endotheli
cell
found
upregul
copd
result
airway
neutrophilia
sever
copd
patient
recruit
neutrophil
lung
activ
secret
granul
protein
myeloperoxidas
mpo
neutrophil
lipocalin
releas
neutrophil
recruit
amplif
inflamm
addit
macrophagederiv
proteas
neutrophil
also
secret
serin
proteas
neutrophil
elastas
ne
cathepsin
g
associ
seriou
alveolar
destruct
emphysema
proteas
activ
may
enhanc
condit
genet
defici
suppress
express
tobacco
smoke
addit
ne
cathepsin
g
involv
stimul
mucu
secret
submucos
gland
goblet
cell
result
airway
mucu
hypersecret
airway
obstruct
copd
nucleotidebind
domain
leucinerichcontain
famili
pyrin
nodlik
receptor
protein
inflammasom
cytosol
multiprotein
complex
consist
inflamm
sensor
protein
adapt
protein
asc
effector
protein
inflammasom
involv
copd
airway
inflamm
regul
product
proinflammatori
cytokin
cytokin
import
neutrophil
surviv
activ
helper
th
cell
interestingli
local
airway
inflammasom
activ
posit
correl
acut
exacerb
lower
airway
microbi
colon
copd
patient
moreov
elastaseinduc
emphysema
model
inflammasom
activ
addit
hyperproduct
mucin
diesel
extract
particl
extracellular
atp
inflammatori
protein
adapt
immun
initi
later
stage
recogn
increas
number
b
lymphocyt
pulmonari
dendrit
cell
dendrit
cell
major
antigenpres
cell
apc
airway
link
innat
adapt
immun
circul
dendrit
cell
express
receptor
recruit
airway
via
dendrit
chemoattract
releas
activ
airway
epitheli
cell
respons
cigarett
smoke
dendrit
cell
act
endocytosi
inhal
irrit
subsequ
process
antigen
peptid
matur
migrat
lymph
node
uncommit
lymphocyt
thereaft
prime
present
antigen
import
cell
activ
releas
dendrit
cell
subsequ
commit
antigenspecif
cell
lineag
ie
helper
cell
wherea
immatur
dendrit
cell
airway
promot
differenti
interestingli
copd
patient
pulmonari
th
cytotox
cell
tc
express
receptor
compar
healthi
individu
enhanc
migrat
toward
chemoattract
activ
releas
alveolar
macrophag
copd
subject
activ
cell
subset
type
releas
perforin
granzym
b
induc
alveolar
cell
apoptosi
contribut
emphysema
parallel
pulmonari
cell
activ
alveolar
macrophagederiv
secret
caus
neutrophil
inflamm
inflammatori
cytokin
also
releas
type
figur
nontyp
h
influenzaedepend
immun
respons
lower
airway
copd
patient
result
inflamm
airway
epithelium
expos
cigarett
tobacco
smoke
display
increas
permeabl
compromis
tight
junction
airway
remodel
goblet
cell
hyperplasia
small
airway
squamou
metaplasia
cigarett
smoke
caus
activ
airway
epithelium
alveolar
macrophag
activ
airway
structur
resid
immun
cell
releas
array
chemotact
factor
respons
recruit
inflammatori
immun
cell
lung
activ
epithelium
produc
fgf
trigger
product
ecm
molecul
fibroblast
increas
deposit
ecm
caus
progress
fibrosi
air
flow
limit
chemokin
ltb
attract
circul
neutrophil
receptor
blt
respect
meanwhil
target
receptor
blood
monocyt
also
releas
recruit
blood
monocyt
differenti
macrophag
airway
tissu
activ
alveolar
macrophag
epithelium
cell
also
releas
inflammasom
neutrophil
surviv
activ
helper
cell
chemokin
releas
macrophag
attract
helper
cell
subset
releas
act
alveolar
epithelium
releas
enhanc
recruit
neutrophil
result
neutrophil
inflamm
activ
neutrophil
thereaft
degranul
releas
myeloperoxidas
mpo
lipocalin
neutrophil
elastas
ne
catheps
cg
matrix
metalloproteas
mmp
granul
product
proteolyt
elastilolyt
aveolar
caus
alveolar
destruct
emphysema
addit
ne
cg
also
target
goblet
cell
submucos
gland
induc
hypersecret
mucu
dendrit
cell
carri
receptor
recruit
airway
tissu
via
chemottract
dendrit
cell
uptak
antigen
smoke
residu
present
antigen
cell
lymph
node
uncommit
lymphocyt
thereaft
prime
present
antigen
activ
deriv
dendrit
cell
profession
antigen
present
cell
apc
matureactiv
cell
express
receptor
chemotact
toward
recruit
lung
tissu
cytotox
cell
subtyp
releas
perforin
granzym
b
result
epitheli
apoptosi
contribut
emphysema
progress
humor
immun
respons
b
cell
activ
enter
circul
via
highendotheli
venul
hev
like
vessel
transport
lung
tissu
organ
lymphoid
follicl
peripher
airway
b
cellderiv
plasma
cell
lymphoid
follicl
releas
iga
secret
airway
lumen
secretori
iga
siga
via
polymer
immunoglobulin
receptor
mucos
antibodi
play
import
role
erad
pathogen
noxiou
antigen
via
immun
exclus
howev
airway
defens
siga
diminish
nthi
iga
proteas
degrad
antibodi
airway
phagocyt
epithelium
follow
exposur
cigarett
smoke
respond
lo
nthi
result
defect
phagocytosi
delay
bacteri
clearanc
airway
suppress
induct
cell
also
lead
predomin
immun
respons
low
product
reduc
cellmedi
immun
kill
nthi
moreov
nthi
downregul
treg
thu
impair
antiinflammatoryproinflammatori
balanc
treg
extens
immunosuppress
activ
treg
diminish
respons
effector
continu
figur
nthi
stimul
lastli
plasma
cell
copd
patient
fail
produc
nthispecif
antibodi
compromis
immunoglobulin
class
switch
impair
host
immun
respons
copd
toward
nthi
infect
label
blue
total
nthi
infect
copd
lung
advers
reduc
product
antimicrobi
peptid
amp
may
explain
ineffici
erad
airway
pathogen
copd
patient
wherebi
persist
nthi
infect
concomitantli
escal
inflamm
thu
exacerb
copd
innat
lymphoid
cell
ilc
involv
homeostasi
lung
immun
regul
epitheli
produc
tslp
stimul
respons
cell
damag
accumul
b
lymphocyt
peripher
airway
within
lymphoid
follicl
associ
airway
autoimmun
progress
copd
airway
tissu
damag
conjunct
impair
tregulatori
cell
treg
relat
cigarett
smoke
contribut
format
autoantibodi
airway
compon
autoantibodi
elastin
epitheli
endotheli
carbonyl
citrullin
protein
found
circul
copd
patient
gener
autoantibodi
might
activ
plasma
exudatederiv
complement
compon
result
chronic
inflamm
consequ
damag
airway
emphysema
progress
physiolog
point
view
modul
inflammatori
process
import
protect
optim
immun
respons
howev
prolong
airway
inflamm
copd
result
impair
homeostasi
lead
seriou
side
effect
sinc
amplifi
tissu
damag
impair
local
immun
defens
abrog
local
immun
system
may
make
airway
copd
patient
suscept
opportunist
recurr
infect
virus
bacteria
turn
might
exacerb
diseas
acut
exacerb
copd
aecopd
episod
acut
symptom
worsen
usual
associ
respiratori
increas
airway
inflamm
nonrespiratori
system
inflammationcomorbid
effect
typic
symptom
aecopd
includ
increas
product
purul
sputum
dyspnea
cough
wheez
symptom
cold
may
last
day
week
commonli
occur
patient
advanc
copd
result
addit
therapi
base
level
exacerb
exacerb
classifi
three
level
accord
gold
mild
diseas
treat
short
act
bronchodil
sab
moder
diseas
sab
combin
antibiot
oral
corticosteroid
final
sever
exacerb
acut
respiratori
failur
requir
emerg
room
visit
eventu
hospit
aecopd
complex
yet
multifactori
consequ
copd
exacerb
could
trigger
infecti
noninfecti
agent
aecopd
known
etiolog
wherea
case
unknown
etiolog
respiratori
tract
infect
major
caus
aecopd
known
etiolog
mainli
attribut
infect
virus
bacteria
atyp
bacteria
detect
convent
gramstain
noninfecti
caus
aecopd
includ
air
pollut
environment
factor
meteorolog
effect
comorbid
patient
partial
contribut
copd
exacerb
respiratori
viral
infect
often
primari
caus
infectiondepend
aecopd
viru
identifi
singl
multipl
infect
strain
copd
patient
exacerb
record
year
common
infect
virus
far
human
rhinoviru
influenza
viru
respiratori
syncyti
viru
wherea
parainfluenza
viru
coronaviru
echoviru
human
metapneumoviru
adenoviru
consider
rare
bacteri
infect
contribut
averag
infect
acut
exacerb
preval
report
rang
commonli
pathogen
bacteri
speci
isol
lower
airway
copd
patient
aecopd
nthi
moraxella
catarrhali
streptococcu
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
klebsiella
pneumonia
suggest
infect
new
strain
infect
speci
rather
new
speci
highli
associ
increas
risk
exacerb
atyp
bacteria
caus
exacerb
chlamydia
spp
legionella
pneumophilia
mycoplasma
spp
contrast
viral
infect
diagnos
copd
patient
stabl
diseas
increas
copd
exacerb
bacteri
colon
airway
common
speci
stabl
diseas
exacerb
henc
precis
direct
role
bacteri
infect
primari
caus
trigger
aecopd
remain
controversi
although
significantli
increas
bacteri
load
observ
exacerb
sever
patient
suggest
bacteria
might
involv
secondari
invad
initi
viral
infect
viral
infect
report
caus
sever
physiolog
chang
lung
turn
facilit
secondari
bacteri
invas
mechan
bacteri
superinfect
describ
h
influenza
pneumonia
aureu
mani
airway
pathogen
firstli
viral
infect
destroy
tight
junction
airway
epitheli
barrier
induc
epithelium
apoptosi
result
onset
airway
epithelium
line
repair
wherebi
slough
dead
cell
would
becom
rich
nutrient
sourc
growth
infect
bacteria
damag
epithelium
line
also
enabl
bacteri
adher
expos
basement
membran
ecm
secondli
demolish
ciliat
clearanc
result
virusdamag
airway
epithelium
line
promot
bacteri
colon
subsequ
epitheli
transmigr
deeper
tissu
lastli
viral
infect
also
detriment
airway
immun
defens
caus
degrad
antimicrobi
peptid
amp
trigger
secret
immun
cell
result
suppress
macrophag
neutrophil
respons
infect
bacteria
thu
enabl
bacteri
evas
airway
immun
defens
nevertheless
viral
bacteri
coinfect
greater
impact
aecopd
airway
inflammatori
respons
bacteria
viru
infect
alon
parallel
coisol
respiratori
virus
bacteria
aecopd
patient
infect
aecopd
also
attribut
impair
function
amp
macrophag
neutrophil
trigger
inhal
irrit
tobacco
smoke
express
microbialinduc
amp
human
suppress
airway
epitheli
cell
expos
cigarett
smoke
alveolar
monocytederiv
macrophag
patient
copd
defect
phagocytosi
bacteria
h
influenza
pneumonia
efferocytosi
apoptot
neutrophil
epitheli
cell
addit
neutrophil
copd
patient
aberr
chemotact
respons
defect
accuraci
factor
contribut
failur
resolv
inflamm
copd
lead
facilit
chronic
microbi
colon
also
exacerb
low
number
cultiv
bacteria
found
healthi
individu
previous
led
conclus
healthi
normal
lung
virtual
steril
hypothesi
current
revis
sinc
introduct
rdna
base
molecular
diagnost
shown
even
healthi
lung
distinct
microbi
commun
differ
seen
upper
respiratori
tract
led
concept
core
human
lung
microbiom
alter
copd
stabl
diseas
exacerb
role
lung
microbiom
pathogenesi
copd
influenc
host
immun
respons
also
suggest
stabil
lung
microbiom
profound
impact
maintain
local
immun
homeostasi
accord
viciou
circl
hypothesi
airway
inflamm
impair
immun
defens
caus
either
viral
infect
irrit
inhal
ecolog
influenc
airway
microenviron
growth
condit
would
eventu
lead
dysbiosi
lung
microbiota
chang
lung
microbiom
would
caus
maladapt
immunolog
respons
result
inflamm
damag
lung
immun
defens
addit
alter
lung
microbiom
chain
event
thu
gener
viciou
circl
contribut
copd
progress
exacerb
sever
studi
document
copd
progress
stabl
state
exacerb
could
induc
microbiota
shift
lower
airway
bronchiol
sputum
throat
alter
microbiom
complex
rich
associ
inflammatori
process
chang
ecm
protein
express
lung
observ
copd
declin
divers
lung
microbiom
report
relat
diseas
sever
inflamm
decreas
lung
function
copd
includ
increas
emphysemat
destruct
bronchial
tissu
remodel
lymphoid
follicl
format
elev
autoantibodi
product
final
increas
neutrophil
extracellular
trap
net
format
airway
anim
model
aecopd
patient
recent
report
lung
microbiom
divers
also
associ
genet
factor
mannosebind
lectin
mbl
defici
also
associ
diseas
sever
exacerb
patient
cystic
fibrosi
bronchiectasi
howev
copd
patient
genet
defici
mbl
less
suscept
haemophilu
spp
colon
lower
risk
exacerb
lung
microbiota
divers
normal
copd
patient
review
focu
nthi
one
domin
genera
rel
abund
total
copddepend
lung
microbiom
due
role
infect
copd
immunolog
respons
microbiolog
h
influenza
recent
review
detail
group
other
gramneg
coccobacillu
commonli
colon
human
nasopharynx
type
capsul
type
af
nonencapsul
strain
nthi
h
influenza
may
caus
invas
mucos
diseas
sinc
introduct
capsul
polysaccharid
conjug
vaccin
type
b
hib
nthi
domin
follow
capsul
type
f
hif
mucos
infect
includ
acut
otiti
media
sinus
exacerb
copd
nowaday
mainli
associ
nthi
also
signific
shift
epidemiolog
sever
invas
diseas
hib
infect
small
children
nthi
adult
common
princip
infect
focu
h
influenza
commun
acquir
pneumonia
cap
wherea
incid
histor
common
diagnos
mening
epiglott
significantli
decreas
patient
underli
condit
notabl
copd
seem
higher
risk
invas
infect
consensu
h
influenza
one
key
bacteri
pathogen
involv
pathogenesi
stabl
copd
diseas
acut
exacerb
howev
rel
abund
signific
nthi
copd
vari
differ
studi
sever
factor
sampl
methodolog
choic
microbiolog
analysi
patient
stabl
diseas
exacerb
subject
previou
antibiot
therapi
tend
affect
outcom
studi
common
sampl
method
lower
respiratori
tract
includ
bronchoscopi
techniqu
protect
specimen
brush
psb
collect
bal
fluid
well
noninvas
method
like
sputum
sampl
method
particularli
sputum
extent
subject
risk
contamin
normal
microbi
flora
oroand
nasopharynx
might
reduc
specif
howev
sever
studi
still
show
distinct
associ
lower
respiratori
tract
sampl
clinic
paramet
copd
patient
make
inform
valuabl
cultiv
bacteria
seldom
found
lower
airway
healthi
individu
wherea
copd
patient
show
bacteri
growth
case
even
stabl
diseas
tabl
top
sever
studi
shown
signific
increas
proteobacteria
phylum
includ
haemophilu
spp
individu
stabl
diseas
aecopd
tabl
nthi
consist
one
predomin
bacteri
speci
isol
cultur
import
pathogen
includ
pneumonia
catarrhali
p
aeruginosa
aecopd
bacteri
load
increas
even
nthi
continu
predomin
speci
furthermor
acquisit
new
nthi
strain
one
studi
link
onset
aecopd
moreov
growth
domin
h
influenza
follow
rhinoviru
infect
observ
sputum
microbiom
patient
copd
chronic
inflamm
character
copd
pathogenesi
caus
signific
chang
pulmonari
tissu
lower
respiratori
tract
patient
suffer
diseas
mark
epitheli
denud
hypersecret
mucu
disproportion
phagocyt
presenc
imbal
antioxidantoxid
alter
milieu
select
specif
bacteri
speci
genet
equip
compet
address
environment
stressor
nthi
common
pathogen
isol
sputum
copd
patient
primari
caus
exacerb
indic
uniqu
abil
colon
persist
chronic
inflam
lower
respiratori
tract
recent
year
great
effort
made
understand
nthi
colon
pulmonari
tissu
addit
regular
arsen
virul
factor
associ
nthi
bacteri
pathogen
undergo
specif
adapt
increas
fit
copd
set
specif
genet
island
includ
ureabcefgh
hgba
iga
report
enrich
nthi
strain
isol
copd
patient
compar
commens
nthi
gene
involv
rais
ph
environ
lipooligosaccharid
lo
synthesi
iron
uptak
immun
evas
attach
host
tissu
valid
find
strengthen
previou
work
identifi
upregul
mani
bacteri
gene
product
growth
copd
sputum
moreov
peroxiredoxinthioredoxin
antioxid
enzym
found
one
enrich
protein
nthi
growth
copd
sputum
suggest
bacteria
upregul
oxid
stresscountermeasur
face
oxid
imbal
diseas
lung
oxid
stress
resist
previous
shown
vital
nthi
surviv
infect
model
semin
investig
pettigrew
et
al
wholegenom
sequenc
wg
conduct
follow
vivo
adapt
nthi
copd
environ
time
sever
interest
find
report
work
firstli
median
durat
persist
pathogen
found
day
could
persist
patient
mani
day
secondli
slippedstrand
mispairingmedi
phase
variat
identifi
primari
genet
adapt
nich
poignantli
gene
affect
regul
mechan
encod
among
other
hmw
adhesin
lo
biosynthesi
iron
uptak
process
identifi
previou
studi
import
copd
adapt
thirdli
somewhat
surpris
observ
limit
number
gene
gainedlost
persist
colon
mean
select
strain
thrive
inflam
lower
airway
occur
onset
colon
final
author
report
genet
chang
occur
investig
vaccin
antigen
persist
infect
fact
might
taken
consider
potenti
vaccin
develop
nthi
anoth
virul
factor
report
murphi
cowork
play
pivot
role
nthi
surviv
copd
set
igaproteas
hydrolyt
enzym
cleav
secretori
iga
siga
antibodi
mucos
epithelium
four
gene
encod
number
differ
variant
endopeptidas
variou
cleavag
site
specif
two
igaa
two
igab
igaa
present
nthi
wherea
igab
present
strain
gene
report
preval
copd
exacerbationcaus
strain
although
vivo
express
level
differ
asymptomat
colon
strain
also
carri
gene
howev
igaproteas
found
promot
intracellular
surviv
nthi
human
epitheli
cell
provid
secondari
function
addit
hydrolysi
iga
antibodi
could
facilit
nthi
growth
inflam
environ
major
persist
nthi
strain
dwell
copd
patient
continu
express
one
variant
enzym
recent
found
phase
variat
offstat
occur
via
slippedstrand
mispair
time
suggest
certain
condit
fit
benefit
express
iga
airway
copd
patient
albeit
specif
process
current
unknown
anoth
interest
aspect
nthi
colon
copd
patient
regard
biofilm
format
nthi
strain
colon
eustachian
tube
caus
otiti
media
known
build
biofilm
situ
howev
strain
isol
copd
patient
tend
significantli
diminish
abil
form
biofilm
compar
invas
strain
isol
otiti
media
patient
suggest
mechan
import
surviv
copd
nich
biofilm
tend
protect
bacteri
commun
extern
assault
find
could
indic
hypermucoid
milieu
copd
airway
sever
impair
abil
deliv
apt
immun
respons
optim
clearanc
resid
microorgan
light
impair
biofilm
format
might
necessari
nthi
persist
particular
environ
infect
nthi
also
shown
reduc
cellular
level
ecadherin
protein
requir
tight
junction
format
epitheli
cell
integr
human
cell
consid
perturb
epitheli
cell
barrier
caus
loss
ecadherin
common
symptom
copd
nthimedi
exacerb
like
contribut
step
copd
pathogenesi
subsequ
denud
epithelium
could
facilit
microbi
colon
basal
lamina
wellestablish
virul
mechan
employ
nthi
pathogen
current
unknown
bacteri
virul
factor
induc
reduct
ecadherin
level
host
summari
investig
recent
year
show
environ
lower
respiratori
tract
copd
patient
select
nthi
strain
upregul
adhesin
modifi
lo
biosynthesi
pathway
increas
antioxid
stress
respons
cellular
invas
strategi
final
trigger
toler
acid
ph
import
colon
mechan
thu
provid
research
viabl
target
develop
novel
therapi
nthi
commens
nasopharyng
site
often
associ
strong
inflammatori
respons
lower
respiratori
airway
especi
patient
copd
bronchiectasi
cystic
fibrosi
pneumonia
idiopath
pulmonari
fibrosi
colon
subsequ
infect
nthi
lower
airway
copd
patient
elicit
episod
immun
respons
orchestr
innat
adapt
immun
nthi
infect
thu
commonli
associ
inflamm
mainli
mediat
transcript
factor
product
proinflammatori
mediat
activ
requir
induct
crosssign
network
cascad
via
activ
prr
pattern
recognit
receptor
host
innat
immun
cell
unresolv
prolong
chronic
inflamm
failur
restor
homeostat
inflammatori
statu
potenti
contribut
exacerb
clearli
shown
murin
copd
simul
model
nthitrigg
inflamm
mice
expos
nthi
lysat
display
inflam
airway
load
increas
level
inflammatori
mediat
phagocyt
infiltr
moreov
multipl
exposur
bacteri
lysat
may
repres
chronic
nthi
infect
caus
extrem
high
infiltr
phagocyt
lymphocyt
airway
particular
mous
model
addit
airway
wall
infect
anim
also
thicken
due
increas
collagen
deposit
fibrosi
reflect
typic
copd
featur
host
immun
respons
specif
interact
nthi
infect
copd
summar
figur
epithelium
alveolar
macrophag
predomin
cell
type
airway
compart
compris
first
line
defens
cellular
immun
respons
potenti
inhal
pathogen
antigen
sens
bacteria
particularli
nthi
lower
airway
initi
via
prr
express
innat
immun
cell
endothelium
addit
epitheli
cell
tlr
prr
sens
stimul
nthideriv
pathogenassoci
molecular
pattern
pamp
play
primari
role
initi
effector
cellular
respons
intracellular
signal
activ
among
differ
tlr
studi
nthi
infect
far
focus
lipoprotein
includ
nthi
lo
potent
immunomodul
activ
respect
describ
sever
studi
airway
epitheli
cell
alveolar
macrophag
interact
nthi
lipoprotein
human
epitheli
cell
type
ii
alveolar
human
middl
ear
epitheli
cell
hmee
caus
activ
via
two
distinct
tlrsignal
pathway
translocationdepend
independ
pathway
nuclear
translocationdepend
pathway
requir
activ
kinas
ikk
complex
second
pathway
mapk
signal
cascad
recruit
direct
nuclear
phosphoryl
thu
activ
branch
pathway
may
occur
activ
kinas
signal
junction
nthi
stimul
via
downstream
activ
pathway
result
express
prostaglandin
promot
inflammatori
respons
stimul
nthi
lo
also
contribut
activ
via
two
signal
pathway
primari
activ
pathway
cascad
altern
pathway
domaincontain
adapterinduc
trif
pathway
activ
phosphoryl
degrad
inhibitor
signal
mediat
effect
innat
immun
respons
lead
upregul
macrophageinflammatori
protein
mip
neutrophil
infiltr
airway
mice
respons
promot
effici
pulmonari
clearanc
bacteria
anim
compar
knockout
mice
recent
studi
jungnickel
et
al
reveal
parallel
infectioninduc
pulmonari
neutrophil
inflamm
nthidepend
stimul
transgen
mous
kra
oncogen
kra
allel
lung
epithelium
addit
promot
prolifer
krasinduc
earli
adenomat
lesion
lung
tlrdepend
manner
associ
role
nthiinduc
airway
inflamm
lung
cancer
progress
howev
support
anoth
recent
cohort
studi
show
lack
differ
nthi
specificantibodi
cancerand
noncanc
copd
patient
lastli
epiderm
growth
factor
receptor
efgr
pathway
also
proinflammtori
effect
upon
interact
nthi
activ
dectindepend
proinflammatori
respons
requir
nthiinduc
phosphoryl
hemimmunoreceptor
tyrosinebas
activ
motif
hemitam
direct
activ
efgr
alveolar
cell
hmee
nthideriv
egflik
factor
shown
contribut
activ
efgrdepend
activ
mediat
via
nuclear
translocationindepend
pathway
involv
signal
pathway
surprisingli
interact
efgr
nthi
also
result
neg
regul
suppress
induct
via
map
kinasedepend
signal
cascad
turn
may
facilit
nthi
infect
actual
compon
nthi
exhibit
egflik
factor
activ
howev
yet
defin
efgrdepend
neg
regul
may
thu
suggest
novel
mechan
target
nthi
immun
evas
attenu
respons
host
prr
despit
contradict
role
efgr
proinflammatori
innat
immun
respons
airway
epithelium
nthi
infect
also
upregul
nthiinduc
inflamm
airway
epithelium
alveolar
macrophag
lead
increas
secret
thu
neutrophil
influx
lung
endogen
inflammatori
mediat
produc
respons
nthi
infect
includ
may
act
synerget
nthi
airway
epitheli
immun
cell
synerget
interact
drive
posit
feedback
loop
amplifi
transcript
activ
proinflammatori
gene
augment
airway
inflamm
synerget
activ
nthi
hmee
normal
human
bronchial
epitheli
nhbe
cell
occur
via
nuclear
translocationdepend
independ
pathway
latter
pathway
involv
mapkextracellular
signal
regul
kinas
kinas
kinas
depend
activ
mapk
kinas
mapk
pathway
howev
synerget
action
nthi
mediat
anoth
mechan
involv
kinas
pka
signal
cascad
pathway
compon
pka
phosphoryl
residu
acetyl
subunit
respect
result
enhanc
dnabind
activ
synerget
action
nthi
enhanc
product
airway
epitheli
cell
interstiti
polymorphonuclear
infiltr
recent
report
coinfect
human
rhinoviru
nthi
airway
epitheli
cell
nhbe
cell
cell
line
also
result
synerget
induct
albeit
exact
mechan
remain
elucid
note
activ
macrophag
also
releas
increas
concentr
enhanc
inflammatori
synerget
effect
surround
immun
cell
final
act
synerget
nthi
upregul
express
amp
via
pathway
note
could
also
act
individu
upregul
express
via
srcdepend
signal
pathway
taken
togeth
synerget
action
may
aid
expans
inflammatori
respons
case
worsen
clinic
outcom
alveolar
macrophag
locat
airparenchyma
interfac
primari
profession
phagocyt
lung
cell
respons
infect
erad
phagolysosom
machineri
releas
plethora
inflammatori
cytokin
chemokin
promot
local
inflammatori
respons
recruit
neutrophil
neutrophil
first
respond
cell
recruit
circul
airway
effici
kill
pathogen
array
microbicid
strategi
nthi
lung
infect
alveolar
macrophag
neutrophil
main
innat
immun
cell
involv
pulmonari
bacteri
clearanc
phagocytosi
also
import
sourc
cytokin
secret
requir
induct
immun
cell
enhanc
bacteri
kill
erad
nthi
alveolar
macrophag
involv
adhes
contact
phagocytosi
phagolysosom
process
bacteria
addit
secret
phagocyt
clearanc
nthi
alveolar
macrophag
orchestr
actin
polymer
plasma
membran
lipid
raft
phosphatidylinositol
signal
cascad
upon
induct
macrophag
prr
nthi
interestingli
respons
nthi
infect
human
alveolar
macrophag
blood
neutrophil
produc
extens
amount
intracellular
extracellular
ro
compon
antimicrobi
defens
lead
format
macrophag
neutrophil
extracellular
trap
met
net
respect
coexpress
enhanc
bacteri
kill
nevertheless
overexpress
mmp
may
advers
result
proteas
imbal
contribut
alveolar
emphysemat
destruct
bronchiectasi
copd
moreov
excess
endogen
ro
product
could
also
introduc
airway
oxid
stress
detriment
caus
chronic
inflamm
tissu
damag
lung
thu
contribut
copd
exacerb
net
format
elicit
mainli
nthi
lo
addit
haemophilu
pamp
sever
studi
king
et
al
reveal
cellmedi
adapt
immun
respons
nthi
airway
infect
patient
idiopath
bronchiectasi
copd
predomin
respons
activ
cell
produc
reduc
level
ligand
increas
level
well
alter
igg
subclass
product
plasma
cell
note
immun
respons
less
effect
suppress
nthi
infect
redirect
immun
respons
domin
protect
ad
mediat
ligand
help
restor
cellmedi
immun
kill
nthi
howev
separ
studi
copd
mous
model
lu
et
al
report
nthi
infect
caus
increas
product
airway
type
interferon
report
dna
nthi
act
pamp
stimul
pathway
thu
product
impact
bacteri
dnainduc
host
immuneinflammatori
respons
may
potenti
induc
respons
requir
investig
copd
patient
also
abnorm
higher
number
treg
cell
myeloidderiv
suppressor
cell
mdsc
exhaust
effector
cell
healthi
individu
cigarett
smokeinduc
antiinflammatori
activ
treg
copd
model
suppress
nthi
infect
pathogen
caus
downregul
biomark
treg
thu
impair
antiinflammatoryproinflammatori
balanc
treg
may
lead
extens
immunosuppress
activ
treg
prolifer
nthi
effector
cell
caus
diminish
respons
effector
cell
sputum
induct
increas
level
recent
report
mucosalassoci
invari
cell
mait
copd
patient
effect
respons
nthi
stimul
thu
produc
increas
level
copd
th
tc
cell
howev
pulmonari
mait
cell
immun
respons
compromis
presenc
corticosteroid
commonli
use
treatment
copd
may
potenti
prone
cellmedi
immun
respons
copd
patient
treat
corticosteroid
interestingli
antigenspecif
cell
nthiimmun
noncopd
mice
model
recogn
homolog
heterolog
strain
nthi
abl
confer
protect
upon
adopt
transfer
howev
unclear
whether
cell
prone
inflammatori
respons
could
train
counteract
nthi
infect
copd
patient
particularli
exacerb
system
humor
immun
respons
nthiinfect
copd
patient
greater
concentr
nthispecif
igg
iga
igm
ige
serum
antibodi
produc
compar
noninfect
control
nthispecif
serum
immunoglobulin
specif
howev
decreas
mucos
antibodi
associ
siga
defici
decreas
total
igg
small
airway
report
copd
patient
might
associ
diseas
sever
importantli
nthispecif
mucos
siga
found
lower
airway
nthiinfect
copd
patient
noncolon
patient
epitheli
polymer
immunoglobulin
receptor
pigr
essenti
gener
mucos
siga
howev
downregul
copd
patient
posit
correl
diseas
sever
increas
level
combinatori
effect
downregul
plgr
elev
contribut
impair
mucos
iga
immun
copd
patient
mous
model
lack
pigr
therefor
devoid
siga
suscept
airway
stimul
nthi
lysat
result
increas
inflamm
airway
neutrophilia
interestingli
introduct
exogen
ad
siga
mitig
airway
inflamm
nthiinfect
copd
patient
greater
airway
inflamm
also
decreas
nthispecif
mucos
bal
fluid
compar
noncolon
patient
interestingli
phenomenon
decreas
nthispecif
antibodi
seem
restrict
airway
sinc
specif
serum
antibodi
affect
therefor
reduc
mucos
igg
unlik
associ
hypogammaglobulinemia
igg
defici
despit
latter
report
contribut
factor
nthi
infect
decreas
airway
iga
might
attribut
express
iga
proteas
nthi
bacteri
iga
proteas
degrad
local
airway
iga
airway
colon
avoid
immun
exclus
siga
reduc
mucos
antibodi
might
promot
host
immun
evas
resist
complementmedi
kill
nthi
thu
enabl
persist
colon
nthi
airway
copd
patient
addit
plethora
variou
virul
mechan
cohort
studi
stabl
copd
patient
augment
airway
inflamm
plasma
fibrinogen
system
inflamm
found
constantli
correl
increas
bacteri
load
higher
number
nthi
greater
impact
pneumonia
catarrhali
trigger
inflammatori
respons
measur
augment
level
inflammatori
cytokin
sputum
includ
mpo
increas
inflammatori
respons
affect
patient
potenti
attribut
persist
colon
nthi
lower
airway
compromis
innat
immun
respons
copd
particularli
decreas
microbicid
activ
regard
one
culprit
persist
airway
colon
nthi
highli
associ
copd
exacerb
figur
whilst
role
macrophag
extracellular
trap
met
kill
nthi
remain
unknown
report
blood
neutrophil
net
copd
patient
defect
kill
plankton
biofilmnetentrap
nthi
respect
seri
studi
berenson
et
al
reveal
alveolar
macrophag
deriv
copd
patient
basic
dysfunct
erad
nthi
intriguingli
express
alveolar
macrophag
copd
patient
intrins
unrespons
potent
immunomodulatori
lipoprotein
lo
respect
caus
decreas
express
tlr
reduc
nuclear
activ
consequ
diminish
respons
alveolar
macrophag
copd
patient
compromis
tlr
express
signal
potenti
contribut
defect
complementdepend
independ
phagocytosi
nthi
defect
phagocytosi
greater
nthi
catarrhali
correl
diseas
sever
interestingli
phagocytosi
disabl
detect
monocytederiv
macrophag
copd
contrast
howev
taylor
et
al
report
monocytederiv
macrophag
copd
patient
also
defect
phagocytosi
nthi
pneumonia
author
also
suggest
defect
monocytederiv
macrophag
attribut
alter
cell
surfac
express
macrophag
receptor
collagen
structur
marco
mannos
receptor
unrespons
copd
alveolar
macrophag
nthi
lipoprotein
lo
might
explain
recent
report
phenomenon
tlr
toler
repetit
stimul
copd
alveolar
macrophag
tlr
ligand
lp
desensit
respect
gener
tlr
toler
moreov
repetit
tlr
stimul
reduc
product
without
affect
constantli
augment
level
alveolar
macrophag
may
provid
altern
explan
diminish
immun
respons
recurrentrepetit
infect
nthi
intrins
reduc
express
tlr
copd
patient
may
also
contribut
impair
pulmonari
immun
respons
thu
facilit
nthi
persist
colon
express
found
lower
sputum
neutrophil
alveolar
macrophag
nasal
epithelium
cell
copd
patient
despit
high
concentr
lack
protect
immun
respons
copd
patient
nthi
infect
might
attribut
upregul
antagonist
irakm
signal
pathway
copd
cell
note
pathway
requir
express
wherea
product
via
signal
pathway
antagonist
prevent
nthi
losinduc
express
thu
reduc
secret
addit
unusu
high
number
treg
copd
patient
also
contribut
effector
cell
dysfunct
predomin
immun
respons
howev
freeman
et
al
report
tc
cell
copd
patient
increas
express
well
cytokin
compar
healthi
individu
may
impli
autoaggress
respons
lung
tc
cell
copd
lung
inflamm
howev
copd
tc
cell
stimul
ligand
yet
toler
agonist
indic
dysfunct
tlr
tlr
toler
cell
despit
high
level
receptor
express
invers
peripher
blood
neutrophil
isol
copd
patient
increas
express
nevertheless
increas
tlr
express
might
improv
microbicid
abil
copd
peripher
neutrophil
probabl
due
inaccur
respons
cytokin
addit
certain
type
snp
snp
also
associ
decreas
lung
function
enhanc
inflammatori
respons
increas
immun
cell
infiltr
copd
interestingli
diminish
respons
copd
alveolar
macrophag
nthi
infect
strong
associ
carriag
polymorph
instead
carriag
also
posit
correl
diminish
lung
function
note
activ
cascad
proinflammatori
cytokin
respons
requir
stimul
microbi
dna
microbicid
malfunct
innat
adapt
immun
cell
also
potenti
link
deleteri
effect
tobacco
smoke
major
risk
factor
copd
report
exposur
tobacco
cigarett
smoke
impair
phagocytosisengulf
nthi
alveolar
macrophag
isol
copd
patient
moreov
chemic
exposur
also
suppress
tlrinduc
product
copd
alveolar
macrophag
prestimul
ligand
lp
phase
flagellin
respect
whole
nthi
bacteria
may
potenti
delay
macrophagedepend
bacteri
clearanc
suppress
effect
cigarett
smoke
macrophagedepend
phagocytosi
due
suppress
signal
cascad
requir
optim
phagocyt
activ
movement
meanwhil
cigarett
smoke
also
inhibit
activ
signal
pathway
thu
dampen
nthi
losinduc
cytokin
product
copd
alveolar
macrophag
diminish
alveolar
macrophag
respons
could
also
relat
anticholinerg
agent
use
copd
patient
result
lower
concentr
nthiinduc
nevertheless
impair
phagocytosi
nthi
copd
alveolar
macrophag
could
improv
presenc
nuclear
erythroid
relat
factor
microrna
interestingli
addit
constant
exacerb
inflammatori
effect
observ
differ
murin
model
studi
gaschler
et
al
observ
rapid
pulmonari
clearanc
nthi
mice
upon
exposur
cigarett
smoke
posit
correl
increas
neutrophilia
anim
bal
fluid
howev
copd
anim
studi
cigarett
smoke
also
impair
product
potenti
antibacteri
activ
delay
airway
clearanc
nthi
interestingli
might
play
protect
role
copd
exacerb
supplement
manag
restor
homeostasi
airway
immun
respons
improv
nthi
clearanc
increas
airway
neutrophilia
might
due
enhanc
product
pulmonari
trigger
cigarett
smoke
may
impli
import
microbicid
role
neutrophil
neutrophilia
compens
copdor
cigarett
smokeassoci
dysfunct
alveolar
macrophag
howev
compens
may
adequ
provid
optim
immun
defens
erad
persist
nthi
lower
airway
colon
sinc
cigarett
smoke
also
profound
suppress
effect
host
adapt
immun
thu
constantli
risk
copd
patient
episod
exacerb
relaps
infect
adapt
immun
cigarett
smoke
impair
antigenspecif
b
cell
respons
nthi
infect
suppress
secret
nthispecif
cell
antibodi
product
b
cell
also
attenu
lower
level
specif
antibodi
compromis
iga
class
switch
recent
previou
cohort
studi
reveal
level
airway
antimicrobi
cathelicidin
copd
patient
increas
gradual
stabl
diseas
exacerb
state
moreov
higher
level
cathelicidin
posit
associ
nthi
airway
colon
sputum
neutrophilia
higher
concentr
particularli
nthiinfect
copd
patient
note
cathelicidin
amp
play
import
role
innat
immun
defens
differ
pathogen
persist
immunomodulatori
properti
iron
plausibl
increas
level
cathelicidin
could
diminish
alter
balanc
lung
microbiota
immuneinflammatori
respons
might
contribut
viciou
circl
thu
consider
increas
risk
nthi
infect
copd
exacerb
moreov
microbicid
properti
cathelicidin
could
compromis
inflammatori
condit
airway
low
ph
effect
cigarett
caus
peptid
citrulin
modif
final
express
amp
human
beta
defensin
copd
airway
epithelium
respons
nthi
infect
also
disturb
cigarett
smoke
insult
airway
cell
also
reduc
express
impair
nthiinduc
activ
thu
larg
bodi
evid
exist
deleteri
effect
tobacco
smoke
antibiot
treatment
aecopd
shown
significantli
reduc
risk
treatment
failur
especi
inpati
sever
exacerb
patient
requir
intens
care
efficac
antibiot
treatment
outpati
exacerb
less
clear
recommend
empir
treatment
use
aecopd
vari
differ
countri
common
antimicrobi
agent
frequent
use
definit
therapi
nthi
includ
aminopenicillin
without
betalactamas
inhibitor
tetracyclin
trimethoprimsulfamethoxazol
fluoroquinolon
addit
clinic
laboratori
standard
institut
clsi
develop
clinic
breakpoint
macrolid
azithromycin
clarithromycin
wherea
european
committe
antimicrobi
suscept
test
eucast
set
clinic
breakpoint
class
antibiot
due
lack
clinic
data
one
studi
show
nthi
frequent
develop
resist
macrolid
prolong
treatment
treatment
failur
may
occur
make
fluoroquinolon
reliabl
erad
copdpati
aminopenicillin
resist
also
common
nthi
isol
express
betalactamas
addit
isol
amino
acid
substitut
penicillinbind
protein
reduc
suscept
agent
fraction
isol
express
betalactamas
stabl
last
year
wherea
increas
seen
isol
display
alter
worrisom
sinc
amino
acid
substitut
also
confer
resist
third
gener
cephalosporin
moreov
seem
correl
isol
express
alter
increas
invas
studi
shown
strain
express
mutat
certain
key
amino
acid
substitut
significantli
higher
rate
invas
bronchial
epitheli
cell
compar
strain
wild
type
howev
mutat
clone
suscept
wild
type
strain
invas
efficaci
increas
suggest
indirectli
link
invas
besid
use
antibiot
acut
manag
copd
exacerb
studi
consid
use
continu
prophylact
antibiot
manag
patient
copd
evid
continu
administr
macrolid
antibiot
would
prevent
futur
exacerb
select
popul
sever
ill
patient
cochran
review
reveal
support
reduc
allcaus
mortal
less
hospit
readmiss
howev
recent
studi
shown
signific
decreas
frequenc
exacerb
hospit
longterm
azithromycin
treatment
chosen
fact
macrolid
antibiot
display
antimicrobi
effect
also
antiinflammatori
immunomodulatori
properti
made
interest
use
prophylact
therapi
shown
azithromycin
inhibit
mucu
hypersecret
respiratori
tract
significantli
inhibit
induct
mucin
secret
human
nasal
epitheli
cell
specif
shown
azithromycin
reduc
nthidepend
induct
express
suppress
transcript
factor
activ
apart
affect
mucu
secret
also
seem
lowdos
azithromycin
abil
improv
phagocytosi
bacteria
airway
macrophag
one
studi
show
azithromycin
concentr
unabl
kill
nthi
still
increas
uptak
rate
bacteria
alveolar
macrophag
enhanc
phagocyt
function
howev
risk
develop
antimicrobi
resist
limit
use
lowdos
azithromycin
sole
immunolog
properti
trigger
interest
find
new
macrolid
substanc
lack
antibiot
effect
sole
interact
airway
immun
system
consider
clinic
problem
caus
nthi
regard
copd
exacerb
otiti
media
prompt
scientif
commun
investig
whether
vaccin
develop
pathogen
search
intensifi
due
steadi
increas
antibiot
resist
trend
invas
infect
caus
nthi
last
decad
wherea
highli
effici
glycoconjug
vaccin
previous
develop
hib
ident
strategi
employ
nthi
due
lack
polysaccharid
capsul
vaccin
develop
effort
thu
concentr
identifi
nthi
surfac
structur
immunogen
low
antigen
variabl
conserv
across
genet
highli
heterogen
speci
sever
promis
vaccin
candid
identifi
last
year
excel
review
elsewher
two
antigen
fuse
one
protein
protein
epila
togeth
protein
current
test
glaxosmithklin
phase
iib
proofofconcept
clinic
trial
random
observerblind
placebocontrol
multicentr
infect
prophylaxi
copd
patient
year
old
notabl
catarrhali
ubiquit
surfac
protein
also
includ
vaccin
immun
respons
exacerbationcaus
pathogen
could
elicit
prepar
clinic
studi
one
current
conduct
nthi
catarrhali
accord
clinicaltrialsgov
investig
ongo
result
current
unknown
due
increas
difficulti
treat
nthi
infect
effici
protect
nthi
vaccin
like
consider
rais
qualiti
life
copd
patient
sinc
nthimedi
exacerb
contribut
progress
diseas
steadi
deterior
pulmonari
capac
patient
prevent
nthi
infect
potenti
slow
debilit
effect
diseas
therefor
critic
continu
line
research
vaccin
obtain
could
also
worth
target
nonconvent
structur
vaccin
secret
enzym
ureas
proven
import
nthi
infect
copd
patient
sever
studi
copd
multifacet
airway
diseas
sever
factor
influenc
clinic
outcom
copd
importantli
crosstalk
intrins
factor
stabil
integr
airway
immun
respons
structur
addit
hereditari
factor
extrins
factor
lung
microbiom
viral
bacteri
infect
meteorolog
factor
noxiou
inhal
determin
fate
lower
airway
opportunist
infect
h
influenza
intriguingli
nthi
one
isol
pathogen
stabl
exacerb
state
copd
persist
airway
colon
nthi
cost
virul
fit
counteract
bactericid
effect
host
immun
respons
advers
impair
defens
mechan
copd
unabl
protect
lung
structur
inhal
physic
assault
also
fail
suppress
nthi
infect
disori
immun
respons
copd
instead
allow
pathogen
caus
harm
inflamm
airway
current
use
bronchodil
inhal
corticosteroid
therapi
limit
efficaci
prevent
diseas
progress
copd
moreov
inhal
corticosteroid
therapi
might
side
effect
may
weaken
immun
respons
henc
investig
need
garner
adequ
knowledg
regard
variabl
immun
network
copd
knowledg
import
platform
effici
drug
design
addit
vaccin
target
nthi
anoth
import
approach
control
infect
exacerb
copd
antibiot
treatment
also
get
dampen
emerg
nthi
antibiot
resist
yc
coordin
draft
major
part
manuscript
prepar
figur
fj
particip
literatur
studi
virul
vaccin
research
nthi
jt
prepar
review
section
nthi
epidemiolog
copd
antibiot
studi
yc
kr
edit
critic
revis
manuscript
author
read
approv
final
manuscript
